1 Expected Dates
PIPELINE
Obesity & liver diseases
Pemvidutide
(ALT-801)
(ALT-801)
MOMENTUM trial: Interim 24-wk weight loss data in Q1 2023
MOMENTUM trial: Top line 48-wk weight loss data in Q4 2023
Pemvidutide
(ALT-801)
(ALT-801)
24-wk NAFLD readout completed Q4 2022
Initiation of Phase 2b NASH trial mid-year 2023
HepTcell™
Top line data readout Q1 2024